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Abstract
Background: Endothelin-1 (ET-1) is important in the pathogenesis of systemic sclerosis (SSc). ET-1 binds two
receptors, endothelin type A (ETA) and endothelin type B (ETB). Dual ETA/ETB receptor antagonists and a selective
ETA receptor antagonist are used clinically to treat SSc, and the effect of these antagonists on fibroblast activation
has been described. However, the role of ETB receptor signaling in fibrogenesis is less clear. This study was
conducted to evaluate the profibrotic function of ETB receptor signaling in a murine model of bleomycin
(BLM)-induced scleroderma.
Methods: We used ETB receptor–knockout (ETBKO) mice, which are genetically rescued from lethal intestinal
aganglionosis by an ETB receptor transgene driven by the human dopamine β-hydroxylase (DβH)-gene promoter,
and wild-type mice with DβH-ETB (WT). BLM or phosphate-buffered saline (PBS) was administered subcutaneously
by osmotic minipump, and skin fibrosis was assessed by dermal thickness, subcutaneous fat atrophy, and
myofibroblast count in the dermis. Dermal fibroblasts isolated from ETBKO and WT mice were cultured in vitro,
stimulated with BLM or ET-1, and the expression of profibrotic genes was compared by quantitative PCR.
Results: Dermal thickness, subcutaneous fat atrophy, and myofibroblast counts in the dermis were significantly
reduced in ETBKO mice compared to WT mice, after BLM treatment. Compared with wild-type, dermal fibroblasts
isolated from ETBKO mice showed lower gene expressions of α-smooth muscle actin and collagen 1α1 in response
to BLM or ET-1 stimulation in vitro.
Conclusions: ET-1–ETB receptor signaling is involved in skin sclerosis and in collagen synthesis by dermal
fibroblasts.
Keywords: Systemic sclerosis, Endothelin type B receptor, Dermal fibroblast
Background
Systemic sclerosis (SSc), a connective-tissue disease of
unknown etiology, is characterized by autoimmunity,
microvascular impairment, chronic inflammation, and
fibrotic changes in the skin and internal organs [1]. The
pathogenesis of SSc has been studied in a bleomycin
(BLM)-induced scleroderma model [2, 3]. Among fibrotic
agents known to contribute to scleroderma, the role of
endothelin-1 (ET-1) in SSc fibrosis has been well de-
scribed [4]. The plasma concentration of ET-1 is elevated
in SSc patients, and endothelin receptor expression is in-
creased in the lungs and skin [5, 6]. ET-1 plays an import-
ant role in murine model of BLM-induced scleroderma
because endothelin receptor antagonist therapy is re-
ported to attenuate skin fibrosis of mice [4]. Recently,
vascular endothelial cell-specific ET-1 knockout mice are
also reported to attenuate skin sclerosis [7]. ET-1, which
was first characterized as a potent vasoconstrictive peptide
derived from endothelial cells, is an important profibrotic
mediator that induces the differentiation of fibroblasts to
myofibroblasts and increases the extracellular matrix.
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Therefore, ET-1 plays a critical role in vascular impair-
ment and fibrosis in SSc patients.
ET-1 binds two receptor subtypes, the endothelin type
A (ETA) and endothelin type B (ETB) receptors [8].
Treatment with a dual ETA/ETB receptor antagonist or a
selective ETA receptor antagonist improves mortality in
patients with pulmonary arterial hypertension [9–11].
ETA receptor signaling is critical for dermal fibroblast
activation [12]. However, the role of ETB receptor signal-
ing in fibrogenesis is less clear.
To investigate the profibrotic activity of the ET-1–ETB
receptor signal in fibrosis, we used endogenous ETB re-
ceptor–knockout (ETBKO) mice with an ETB receptor
transgene driven by the human dopamine β-hydroxylase
(DβH) gene promoter, which generated “rescued” ETB-
knockout mice [13–15]. ETB-receptor mutant mice and
general (not rescued) ETBKO mice, which have aganglio-
nic megacolon and white spotting on the coat, die before
reaching adulthood because ETB receptor signaling is
important in generating melanocytes and enteric neu-
rons [16]. In the “rescued” ETBKO mice, a functional
ETB receptor is expressed only in the enteric nervous
system; other tissues lack ETB receptors. These mice
survive into adulthood [17].
Here we show that ETBKO mice were resistant to
BLM-induced scleroderma, and that compared to WT
mice, ETBKO mice showed less fibroblast activation and
myofibroblast formation in response to BLM or ET-1.
Methods
Animals
The mice were housed in the animal facility of Kobe
Pharmaceutical University, with a 12-h dark/light cycle
and ad libitum water and food. Heterozygous ETBKO
mice (ETB+/-) on a C57BL/6 J genetic background were
generated as described previously [17, 18]. The human
DβH gene promoter–regulated ETB receptor transgene
(DβH-ETB) and ETB+/- with DβH-ETB were generated
as described previously [13–15]. ETB+/- mice were
crossed with DβH-ETB mice to obtain three genotypes:
wild-type ETB+/+ with DβH-ETB (WT mice), ETB+/-
with DβH-ETB (heterozygous KO mice), and ETB-/- with
DβH-ETB (ETBKO mice). The ETBKO mice had a partly
white coat that distinguished them from heterozygous
KO and WT mice. All experimental protocols were
approved by the Ethics Review Committee for Animal
Experimentation of Kobe Pharmaceutical University.
Reagents and antibodies
BLM and ET-1 (H-6995) were purchased from Nippon-
Kayaku (Tokyo, Japan) and Bachem (Bubendorf,
Switzerland), respectively. Dulbecco's modified Eagle's
medium (DMEM) (Nissui-Seiyaku, Tokyo, Japan), RPMI
1640 (Wako Pure Chemical Industries, Osaka, Japan), fetal
bovine serum (FBS) (MP Biomedicals, Santa Ana, CA,
USA), 1 % penicillin–streptomycin (Lonza, Basel,
Switzerland), L-glutamine (Thermo Fisher Scientific,
Waltham, MA, USA), and type 1 collagenase (Worthington
Biochemical Corporation, Lakewood, NJ, USA) were also
used. Bovine serum albumin (BSA), 2 M acetic acid, and
dispase were purchased from Sigma-Aldrich (St. Louis,
MO, USA). For immunohistochemistry experiments, anti-
alpha smooth-muscle actin (αSMA) antibody (ab32575),
anti-collagen 1 antibody (ab21286), anti-CD3 antibody
(ab16669), anti-F4/80 antibody (ab111101) and rabbit
polyclonal IgG (ab27472) were purchased from Abcam
(Cambridge, UK), and anti-myeloperoxidase antibody
(PA5-16672) purchased from Thermo Fisher Scientific
(Waltham, MA, USA). A rabbit ABC Staining System
(sc-2018) was purchased from Santa Cruz Biotechnology
(Dallas, TX, USA).
BLM administration
BLM was dissolved in phosphate-buffered saline (PBS).
BLM or PBS was administered with osmotic minipumps
according to previous reports with minor modifications
[19–21]. Briefly, osmotic minipumps (Alzet2001; Durect,
Cupertino, CA, USA) containing 200 μl of BLM (125 mg/
kg) or PBS were implanted subcutaneously onto the back
of WT or ETBKO mice aged 6–10 weeks; this was counted
as day 0. The pumps delivered 1.0 μg/h for 7 days. The
mice were sacrificed on day 28, and skin and lung tissues
were taken. Skin samples were taken a short distance from
the osmotic minipump to obtain samples that were not af-
fected by pump implantation.
Histology and immunohistochemistry
The skin and lung samples were fixed in 4 % paraformalde-
hyde, embedded in paraffin, sectioned, and stained with
Masson’s trichrome. To evaluate the BLM-induced sclero-
derma, we assessed dermal thickening and subcutaneous fat
atrophy by measuring the distances between the epidermis
and dermis and between the dermis and subcutaneous fat
at 40× magnification. The degree of lung fibrosis was quan-
tified using the Ashcroft score at 40× magnification [22].
Collagen 1 deposition area in the dermis was measured with
ImageJ software (National Institutes of Health). Fibroblast
activation was assessed by αSMA immunohistochemical
staining of the skin sections, and αSMA-positive myofibro-
blasts in the dermis were counted at 100× magnification.
To examine whether ETB receptor is involved in the inflam-
mation of this model, we counted myeloperoxidase-positive
neutrophils, CD3-positive T lymphocytes and F4/80-positive
macrophages in the dermis at 100× magnification.
Collection of bronchoalveolar lavage fluid (BALF)
To evaluate lung inflammation, a cell count of BALF was
performed. Immediately after the mice were sacrificed, a
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20-gauge intravenous catheter was inserted into the tra-
chea. A total of 0.5 ml of PBS was instilled three times
and withdrawn from the lung via an intratracheal cannula.
After BALF was centrifuged, the pellet was resuspended in
1 ml of PBS. Total BALF cells were counted with a
hemocytometer. The BALF solutions were stained with
May-Giemsa staining after cytospin centrifuge, and the
white blood cell differentiation was evaluated by morpho-
logical criteria using a light microscope.
Murine dermal fibroblast isolation and culture
Dermal fibroblasts were isolated from WT and ETBKO
mice at 3–4 weeks of age according to previous reports,
with minor modification [23]. Skin samples were placed
dermis-down in culture dishes containing RPMI + 3.6 %
dispase, and incubated overnight at 4 °C. The dermis
was separated from the epidermis, placed in RPMI +
0.05 % type I collagenase, and incubated at 37 °C for
30 min. The cell suspension was filtered through sterile
gauze into a 50-mL conical tube. After adding an equal
volume of DMEM+ 10 % FBS containing penicillin,
streptomycin, and L-glutamine, the suspension was cen-
trifuged at 200 × g for 10 min. Fibroblasts were resus-
pended in DMEM+ 10 % FBS, plated in 100-mm culture
dishes, and incubated at 37 °C in 5 % CO2 and 95 %
room air. For in vitro experiments, fibroblasts were
seeded into 6-well plates (1 × 105 per well) and incubated
in DMEM+ 10 % FBS at 37 °C in 5 % CO2. When the fi-
broblasts had grown to approximately 80 % confluence,
the medium was changed and the fibroblasts were
treated with 20 μg/ml BLM or 500 nM ET-1 for 24 h.
The BLM was dissolved in DMEM without FBS; the ET-
1 was dissolved in 0.1 % acetic acid + 0.01 % BSA.
Quantitative real-time polymerase chain reaction (PCR)
Total RNA was isolated from fibroblasts using an
RNeasy Mini kit (Qiagen, Hilden, Germany), followed by
cDNA synthesis using a QuantiTect Reverse Transcrip-
tion kit (Qiagen). PCR reaction mixtures were prepared
using the QuantiTect SYBR Green PCR kit (Qiagen),
followed by quantitative PCR on a PikoReal system
(Thermo Fisher Scientific). The following primer pairs
were used: collagen 1α1 (Col1α1), 5’-TGACTGGAA
GAGCGGAGAGTACT-3’ (forward) and 5’-GGTCTGA
CCTGTCTCCATGTTG-3’ (reverse); αSMA, 5’-AGA
GACTCTCTTCCAGCCATC-3’ (forward) and 5’-
GACGTTGTTAGCATAGAGATC-3’ (reverse); ET-1, 5’-
GTGTCTACTTCTGCCACCTGGACAT-3’ (forward) and
5’-GGGCTCGCACTATATAAGGGATGAC-3’ (reverse);
endothelin receptor type A (EDNRA), 5’-CCTTAT
CTSCGTGGTCATTG-3’ (forward) and 5’-ACTGAGAG
CACAGAGGTTC-3’ (reverse); endothelin receptor type
B (EDNRB), 5’-GGAATCACAGTGCTGAGTC-3’ (for-
ward) and 5’-CTTTGTAGTCCGACGTAATC-3’ (reverse);
glyceraldahyde-3-phosphate dehydrogenase (GAPDH), 5’-
AACTTTGGCATTGTGGAAGG-3’ (forward) and 5’-
ACACATTGGGGGTAGGAACA-3’ (reverse). GAPDH
was used as an internal control to normalize the amount
of loaded , complementary DNA (cDNA).
Measurement of soluble collagen content
Sircol collagen assay (Biocolor Ltd., Belfast, Northern
Ireland) was used to quantify soluble collagen contents
in fibroblast culture supernatant according to the manu-
facturer’s instructions with minor modification. Briefly,
200 μl of supernatant was mixed with 1 ml of Sircol dye
reagent for 30 minutes. After centrifugation, the pellets
were dissolved in 1 ml Sircol alkali reagent and vortexed.
Relative absorbance was measured at 540 nm.
Statistical analysis
Data are presented as mean ± standard error of the mean
(SEM). Differences between groups were analyzed by
Student’s t test using GraphPad Prism 5 software
(GraphPad Software Inc., La Jolla, CA, USA) and p <
0.05 was considered statistically significant.
Results
ETBKO mice resisted BLM-induced scleroderma
WT and ETBKO mice were treated with BLM or PBS by
osmotic minipump. No mice died due to the osmotic
minipump implantation or BLM administration. To
examine the biological significance of ETB receptor sig-
naling after BLM administration, we measured body-
weight changes from day 0 to day 28. ETBKO mice were
smaller than WT mice of the same age, and ETBKO
mice gained less body weight than did WT mice when
treated with PBS. However, while BLM-treated WT mice
did not gain body weight, BLM-treated ETBKO mice
gained weight similarly to the PBS-treated ETBKO mice
(Fig 1b).
To determine the ETB receptor’s role in BLM-induced
scleroderma, skin specimens were obtained from each
group on day 28 after implanting the osmotic minipump.
The skin samples were stained with Masson’s trichrome
to evaluate the dermal thickness and subcutaneous fat
atrophy. In WT mice, BLM treatment increased the dis-
tance between the epidermis and dermis, and reduced
the distance between the dermis and subcutaneous fat.
In contrast, these distances did not change significantly
in the ETBKO mice treated with PBS or BLM (Fig. 2a-c).
Likewise, collagen 1 deposition area in the dermis was
increased by BLM-treatment in WT mice, but the incre-
ment was not seen in ETBKO mice (Fig. 2d). These re-
sults suggested that ETB receptor signaling is associated
with BLM-induced skin sclerosis. Also lung fibrosis and
inflammation were evaluated, but neither cell counts in
BALF nor lung histological scores were not significantly
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different between WT and ETBKO with BLM treatment
(Additional file 1: Figure S1).
Inhibited fibroblast activation protects ETBKO mice
against BLM-induced scleroderma
BLM-induced scleroderma is associated with the differ-
entiation of fibroblasts into myofibroblasts. These myofi-
broblasts, which are identified by αSMA expression,
promote fibrosis by producing collagen and other
extracellular matrix components [24, 25].
To determine whether ETB receptor signaling contributes
to BLM-induced fibroblast differentiation, we counted the
number of αSMA-positive cells in the dermis of BLM- or
PBS-treated WT and ETBKO mice. BLM increased the
number of αSMA-positive myofibroblasts in the WT but
not ETBKO dermis, indicating that ETB is involved in myo-
fibroblast formation (Fig. 3).
Inflammatory cell filtration in the dermis was counted
to determine whether the degree of inflammation was
different between WT and ETBKO skin fibrosis. The
numbers of myeloperoxidase-positive neutrophils, CD3-
positive T cells and F4/80-positive macrophages in the
dermis were significantly increased when treated with
BLM. However, the numbers of these inflammatory cells
Fig. 1 Study design and body-weight changes of each mice group after BLM treatment. a Summary of this experimental model and sample
number of each group. Osmotic pumps containing 200 μl of BLM (125 mg/kg) or PBS were implanted subcutaneously onto the back of WT or
ETBKO mice on day 0. Pumps deliver their contents 1.0 μg/h for 7 days. Mice were sacrificed on day28. b Body-weight changes from day 0 to day
28 in WT and ETBKO mice. The body-weight change was calculated as [(body weight on day 28) − (body weight on day 0)] × (body weight on
day 0)-1 × 100 (%). Each dot indicates the body-weight change in an individual mouse (*p < 0.05). BLM bleomycin, DβH-ETB endothelin type B
receptor transgene driven by the human dopamine β-hydroxylase gene promoter, ETBKO endothelin type B receptor knockout, PBS phosphate-
buffered saline, WT wild-type
Fig. 2 ETBKO mice resist BLM-induced skin sclerosis. a Representative images of dermis sections stained with Masson's trichrome at 40× magnification.
b Changes in dermal thickness (epidermal–dermal distance) and c subcutaneous fat atrophy (dermal–subcutaneous fat distance) in BLM- or PBS-
treated WT and ETBKO mice; values are shown as the mean fold change from PBS-treated WT (WT-PBS) mice. d Collagen 1 deposition area in dermis
of each mice group. (*p < 0.05) (n = 5–10 mice per group). BLM bleomycin, ETBKO endothelin type B receptor knockout, PBS phosphate-buffered saline,
WT wild-type
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were not different between WT and ETBKO mice both
before and after BLM treatment (Fig. 4).
Collectively ETB receptor signaling seemed to contrib-
ute to fibroblast activation independent of inflammation.
The ETB receptor is associated with dermal fibroblast
activation and collagen synthesis in response to BLM or ET-1
Because fibroblasts play a critical role in fibrosis, we next
examined the characteristics of dermal fibroblasts from
WT and ETBKO mice. ET-1 or BLM stimulation is re-
ported to induce fibroblasts to express profibrotic genes
[12, 26]. Thus, we isolated dermal fibroblasts from WT
and ETBKO mice and assessed their activation and colla-
gen synthesis in response to ET-1 or BLM in vitro.
Dermal fibroblasts from ETBKO mice expressed little or
no EDNRB mRNA but expressed EDNRA normally, as
expected (Fig. 5a, b).
BLM stimulation induced Col1α1 and ET-1 gene
expression in fibroblasts from WT mice, but not in
those from ETBKO mice. When stimulated with BLM,
WT fibroblasts expressed the αSMA gene at significantly
higher levels than did ETBKO fibroblasts (Fig. 5c-e).
ET-1 stimulation induced Col1α1 expression in WT fi-
broblasts. ET-1 also tended to induce αSMA mRNA in
WT fibroblasts, although this increase did not reach
statistical significance. ET-1 stimulation did not influ-
ence the Col1α1 or αSMA expression in ETBKO fibro-
blasts (Fig. 6a, b).
Fig. 3 Fewer αSMA-expressing myofibroblasts are observed in the dermis of ETBKO than WT mice after BLM treatment. a Representative images
showing the immunohistochemical staining of skin samples for αSMA (upper) and isotype (lower) at 100× magnification. Red arrows indicate
myofibroblasts (αSMA-expressing spindle-shaped cells). b Average myofibroblast counts per field of view in the dermis, counted at 100×
magnification (*p < 0.05); n = 5–10 mice per group. BLM bleomycin, HPF high-power field, ETBKO endothelin type B receptor knockout, PBS
phosphate-buffered saline, WT wild-type
Fig. 4 Infiltration of inflammatory cells in the dermis of WT and ETBKO mice after BLM treatment. The average cell counts of a myeloperoxidase,
b CD3, and c F4/80-positive cells in the dermis. The cells were counted per field of view at 100× magnification; n = 5–10 mice per group. (*p < 0.05).
BLM bleomycin, ETBKO endothelin type B receptor knockout, HPF high-power field, PBS phosphate-buffered saline, WT wild-type
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Fig. 5 Knockout of the ETB receptor signal reduces the activation of skin-derived fibroblasts in response to BLM. a EDNRA and b EDNRB mRNA
levels in skin-derived fibroblasts from WT and ETBKO mice (n = 5 each). c-e BLM-induced fibroblast activation in WT and ETBKO mice (n = 6–9
each), determined by the gene expression levels of Col1α1, αSMA, and ET-1. Values show the mean mRNA levels relative to WT without stimulation
(*p < 0.05). f Soluble collagen production from WT and ETBKO (n = 4 each) fibroblasts with or without BLM treatment (
*p < 0.05). WT wild-type,
αSMA α-smooth muscle actin, BLM bleomycin, Col1α1 collagen 1α1, ET-1 endothelin-1, ETBKO endothelin type B receptor knockout, PBS
phosphate-buffered saline
Fig. 6 Knockout of the ETB receptor signal reduces the activation of skin-derived fibroblasts in response to ET-1. a, b ET-1-induced fibroblast activation
in WT and ETBKO mice (n = 4 or 5 each), determined by the gene expression levels of Col1α1, αSMA. Values show the mean mRNA levels relative to WT
without stimulation (*p < 0.05). c Soluble collagen production from WT and ETBKO (n = 4 each) fibroblasts with or without ET-1-treatment (
*p < 0.05).
αSMA α-smooth muscle actin, BLM bleomycin, Col1α1 collagen 1α1, ET-1 endothelin-1, ETBKO endothelin type B receptor knockout, PBS phosphate-
buffered saline, WT wild-type
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Next, we measured soluble collagen content in the
supernatant with Sircol collagen assay to assess whether
BLM or ET-1 stimulation increases collagen production
by fibroblasts. BLM or ET-1 treatment of WT fibroblasts
significantly induced collagens. Increase in collagen pro-
duction by BLM or ET-1 stimulation was not seen in
ETBKO fibroblasts (Figs. 5f and 6c). Collectively, ETBKO
fibroblasts showed less profibrotic properties in response
to BLM or ET-1 than WT.
Discussion
In this study, we demonstrated for the first time with
genetic ETBKO mice that ETB receptor signaling in the
presence of the ETA receptor promotes fibrosis in BLM-
induced scleroderma. Myofibroblast formation was inhib-
ited in ETBKO mice, allowing them to resist BLM-induced
skin fibrosis. At least one mechanism of the ETB receptor
appears to function through dermal fibroblasts, because the
ETBKO fibroblasts did not respond to BLM or ET-1 stimu-
lation, whereas WT fibroblasts showed increased Col1α1
and αSMA expression in vitro.
Rescued ETBKO rats and mice, like those used in this
study, are useful for investigating ETB receptor signaling.
ETBKO rats show deteriorating health due to hypoxia-
induced pulmonary hypertension, and ETBKO mice
show worsened vascular remodeling in a carotid artery
ligation model [27, 28]. Our study is the first to demon-
strate that the ETB receptor is critical for BLM-induced
scleroderma using ETBKO mice.
ET-1 is important in fibrosis because it induces colla-
gen production and myofibroblasts. We found that in
WT fibroblasts, BLM induced ET-1, which in turn in-
duced collagen production. On the other hand, ETBKO
fibroblasts did not produce collagen when stimulated by
ET-1, indicating that ETB is indispensable for the ET-1-
induced collagen production. Thus, the ET-1–ETB sys-
tem is critical for the collagen production by fibroblasts.
We showed that myofibroblast formation was strongly
inhibited in the ETBKO mice in vivo. In addition,
ETBKO fibroblasts did not express αSMA mRNA in re-
sponse to BLM or ET-1. These results indicate that ETB
is involved in myofibroblast formation. In our experi-
ments, ET-1’s induction of αSMA in WT fibroblasts in
vivo was stronger than that in vitro. This was not sur-
prising, because there are multiple sources of myofibro-
blasts in vivo, including tissue-resident fibroblasts [29],
epithelial or endothelial cells transitioning into mesen-
chymal cells (EMT or EndoMT) [30–33], or bone
marrow-derived circulating fibrocytes [34, 35]. Thus, we
believe that ETB is involved in myofibroblast formation
from various types of cells.
Myofibroblast precursors differ in various tissues. For
example, resident fibroblasts are the main contributors
to myofibroblasts in lung fibrosis [36], and hepatic
stellate cells are the most important source of myofibro-
blasts in liver fibrosis [37]. Although a recent study found
that adipocytes differentiate into myofibroblasts in dermal
fibrosis [38], the primary source of myofibroblasts in der-
mal fibrosis remains unclear. ETB receptor signaling seems
to be important in liver and cardiac fibrosis [39–41], but
not renal fibrosis [42]. The difference of the skin and lung
fibrosis might come from the difference in both myofibro-
blast precursor and contribution of ETB receptor signaling
in the organ. Further investigation is needed to reveal
which cells are responsible for generating dermal myofi-
broblasts, and how the ETA and ETB receptors are in-
volved in dermal or other organ fibrogenesis.
In dermal fibroblasts, both ETA and ETB receptor
signaling are reported to be necessary for ET-1 to exert its
profibrotic effect [12]; in that study, neither ETA nor ETB
receptor selective antagonists inhibited the collagen syn-
thesis in dermal fibroblasts stimulated with ET-1. Our
data appear to conflict with that study; this discrepancy
might be due to differences between a pharmacological
blockade and genetic knockout. The genetic knockout is
assumed to affect permanently and completely, while the
effect of pharmacological blockade is usually temporary
and depends on affinity. We did not perform in vivo and
in vitro study with the ETB selective antagonist, because it
was reported that existing inhibitors could not suppress
the fibroblast activation in vitro as mentioned above. We
hope that new ETB selective antagonists that suppress
fibroblast function will be developed.
Clinically, dual ETA/ETB receptor antagonists (bosentan,
macitentan) and a selective ETA receptor antagonist
(ambrisentan) improve the hemodynamics, exercise cap-
acity, and survival rate in patients with pulmonary arterial
hypertension [9–11]. These ET receptor blockers are also
effective for preventing and improving digital ulcers in
SSc patients [43, 44]. Currently, there is no selective ETB
receptor antagonist that can be safely administered to
humans. However, our study suggests that ETB receptor
blockade is a potential pharmaceutical treatment for pro-
gressive skin fibrosis in SSc patients.
Conclusions
This study described that ETBKO mice were resistant to
BLM-induced skin sclerosis and that ETBKO mice
showed less fibroblast activation and myofibroblast for-
mation in response to BLM or ET-1. Thus, ET-1–ETB
receptor signaling is involved in skin sclerosis and in
collagen synthesis by dermal fibroblasts.
Additional file
Additional file 1: Figure S1. BLM-induced lung inflammation and fibrosis
of WT and ETBKO mice. (A) Total cell, (B) macrophages, (C) neutrophils, and
(D) lymphocytes counts in BALF collected from WT and ETBKO with PBS or
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BLM treatment (n = 5–10 mice per group) on day28 after osmotic
implantation (*p< 0.05). (E) Representative images of lung sections stained
with Masson's trichrome at 40 ×magnification. (F) Ashcroft score of WT and
ETBKO mice with PBS or BLM treatment (n = 5–10 mice per group) (
*p< 0.05).
BLM bleomycin, ETBKO endothelin type B receptor knockout, PBS phosphate-
buffered saline, WT wild- type. (TIF 1160 kb)
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